Novel Variant C.7795-1G>A of COL7A1 Gene in a 12-month-old Female Child with Recessive Dystrophic Epidermolysis Bullosa Treated with Dupilumab
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Shao L, Zhong D, Liu Y, Wang J
. Dupilumab as a novel therapy for epidermolysis bullosa pruriginosa. Int J Dermatol. 2023; 62(10):e542-e545.
DOI: 10.1111/ijd.16752.
View
2.
Zhou A, Little A, Antaya R
. Epidermolysis bullosa pruriginosa treated with dupilumab. Pediatr Dermatol. 2020; 38(2):526-527.
DOI: 10.1111/pde.14493.
View
3.
Sun X, Zhang J, Yang Q, Lin J
. Treatment of epidermolysis bullosa simplex with dupilumab. J Dermatol. 2023; 51(4):e131-e132.
DOI: 10.1111/1346-8138.17037.
View
4.
Zhang L, Wang S, Chen Q, Xiang L
. A case of junctional epidermolysis bullosa intermediate with collagen XVII deficiency treated with dupilumab. J Dermatolog Treat. 2023; 34(1):2253943.
DOI: 10.1080/09546634.2023.2253943.
View
5.
Clawson R, Duran S, Pariser R
. Epidermolysis bullosa pruriginosa responding to dupilumab. JAAD Case Rep. 2021; 16:69-71.
PMC: 8427235.
DOI: 10.1016/j.jdcr.2021.07.036.
View